CervoMed posts Q1 net loss $4.9M, secures $50M ATM facility; reports positive Phase 2b DLB results

CervoMed Inc.

Entered $50M at-the-market offering agreement with Leerink Partners; 3% commission on sales.
Cash and marketable securities $35.2M at March 31, 2025, down from $38.9M at Dec 31, 2024; runway into mid-2026.
Net loss $4.9M for Q1 2025 compared to $2.5M in Q1 2024, driven by higher R&D costs for neflamapimod.
Sixteen-week extension data from RewinD-LB Phase 2b showed CDR-SB improvement (p<0.001 vs old capsules, p=0.003 vs placebo); Phase 3 planned in mid-2026.
Initiating Phase 2a trials in primary progressive aphasia (mid-2025) and ischemic stroke recovery (recently started).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.